Oxford Immunotec Global PLC (OXFD)’s Bearish Double Bottom Chart Pattern Points to Higher Stock Risks

March 18, 2018 - By wolcottdaily

Investors sentiment decreased to 1.13 in 2017 Q3. Its down 0.14, from 1.27 in 2017Q2. It worsened, as 3 investors sold Oxford Immunotec Global PLC shares while 27 reduced holdings. 12 funds opened positions while 22 raised stakes. 22.51 million shares or 13.08% more from 19.91 million shares in 2017Q2 were reported.
Financial Bank Of America Corporation De holds 0% or 1,233 shares in its portfolio. Nationwide Fund Advsr stated it has 12,689 shares or 0% of all its holdings. Citigroup reported 0% in Oxford Immunotec Global PLC (NASDAQ:OXFD). State Common Retirement Fund stated it has 0% in Oxford Immunotec Global PLC (NASDAQ:OXFD). C World Group Inc A S stated it has 183,235 shares. Alyeska Invest Gp L P invested in 1.36M shares or 0.18% of the stock. Deutsche Bank & Trust Ag has 29,494 shares for 0% of their portfolio. Wells Fargo & Company Mn has 38,720 shares for 0% of their portfolio. Rhumbline Advisers has invested 0% of its portfolio in Oxford Immunotec Global PLC (NASDAQ:OXFD). Ascend Cap Limited Co has 0.03% invested in Oxford Immunotec Global PLC (NASDAQ:OXFD) for 51,655 shares. Driehaus Capital Mngmt Lc has invested 0.19% in Oxford Immunotec Global PLC (NASDAQ:OXFD). Tiaa Cref Inv Mngmt Ltd Limited Liability Company reported 84,854 shares or 0% of all its holdings. D E Shaw And Com Inc reported 0% in Oxford Immunotec Global PLC (NASDAQ:OXFD). Schwab Charles Investment Mgmt has invested 0% in Oxford Immunotec Global PLC (NASDAQ:OXFD). Essex Inv Mngmt Llc invested in 0.32% or 139,009 shares.

Since October 2, 2017, it had 0 insider purchases, and 2 insider sales for $958,971 activity. 55,000 shares valued at $922,933 were sold by Wrighton-Smith Peter on Monday, October 2.

The chart of Oxford Immunotec Global PLC (OXFD) shows a double bottom with $13.26 target or 3.00 % below today’s $13.67 share price. The 7 months chart pattern indicates high risk for the $353.67 million company. It was reported on Mar, 18 by Finviz.com. If the $13.26 price target is reached, the company will be worth $10.61 million less. Double bottoms are rare but powerful chart patterns.

The stock increased 3.25% or $0.43 during the last trading session, reaching $13.67. About 260,146 shares traded or 25.59% up from the average. Oxford Immunotec Global PLC (NASDAQ:OXFD) has risen 54.26% since March 18, 2017 and is uptrending. It has outperformed by 37.56% the S&P500.

Analysts await Oxford Immunotec Global PLC (NASDAQ:OXFD) to report earnings on May, 1. They expect $-0.38 EPS, down 5.56 % or $0.02 from last year’s $-0.36 per share. After $-0.34 actual EPS reported by Oxford Immunotec Global PLC for the previous quarter, Wall Street now forecasts 11.76 % negative EPS growth.

Oxford Immunotec Global PLC (NASDAQ:OXFD) Ratings Coverage

Among 4 analysts covering Oxford Immunotec (NASDAQ:OXFD), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Oxford Immunotec has $22.0 highest and $15.0 lowest target. $17.75’s average target is 29.85% above currents $13.67 stock price. Oxford Immunotec had 10 analyst reports since July 19, 2017 according to SRatingsIntel. The firm earned “Buy” rating on Monday, January 22 by Cowen & Co. The firm has “Buy” rating by BTIG Research given on Thursday, September 28. The rating was maintained by Cowen & Co on Wednesday, September 27 with “Buy”. The stock has “Buy” rating by Piper Jaffray on Monday, January 8. Cowen & Co maintained Oxford Immunotec Global PLC (NASDAQ:OXFD) on Tuesday, October 31 with “Buy” rating. The firm has “Buy” rating by Cowen & Co given on Wednesday, July 19. The firm has “Buy” rating given on Tuesday, October 31 by Robert W. Baird. Robert W. Baird maintained the shares of OXFD in report on Thursday, October 19 with “Buy” rating. The firm has “Buy” rating given on Wednesday, August 16 by Cowen & Co.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.